Trial Profile
A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms GEMINI 1 ACS; GEMINI ACS 1
- Sponsors Janssen Research & Development
- 01 Sep 2020 Results of integrated analysis from six clinical studies: ATLAS-1, ATLAS-2, COMPASS, COMMANDER HF, GEMINI ACS1 and PIONEER AF-PCI presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 12 Mar 2018 Results of pooled analysis of ATLAS-ACS-TIMI-46, ATLAS-ACS-2-TIMI-51, GEMINI-ACS-1, and COMPASS trial comparing efficacy and safety of Rivaroxaban based dual pathway antithrombotic therapy Vs dual antiplatelet therapy presented at the 67th Annual Scientific Session of the American College of Cardiology
- 18 Mar 2017 According to a Janssen Pharmaceuticals media release, this trial is part of Janssen's EXPLORER clinical research program.